Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sucampo/Takeda’s Amitiza Gains IBS-C Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

Approval expands the target population for lubiprostone by about 20 million patients, Sucampo commercial head tells “The Pink Sheet” DAILY.

You may also be interested in...



Ironwood Poised To Move Linaclotide To Phase III In IBS-C

Partnered in the U.S. with Forest, firm formerly known as Microbia seeks to join Amitiza in space vacated by Zelnorm.

Ironwood Poised To Move Linaclotide To Phase III In IBS-C

Partnered in the U.S. with Forest, firm formerly known as Microbia seeks to join Amitiza in space vacated by Zelnorm.

Ironwood Poised To Move Linaclotide To Phase III In IBS-C

With a pair of pivotal Phase III trials in chronic constipation under way, Ironwood Pharmaceuticals reported success Oct. 7 in Phase IIb testing of linaclotide in constipation-predominant irritable bowel syndrome. Partnered in the U.S. with Forest Laboratories, the firm plans to begin two pivotal Phase III trials in IBS-C by next January

Related Content

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel